Sanacorp acquires von der Linde
Sanacorp has acquired fellow German drug wholesaler von der Linde for an undisclosed fee. The firm says the acquisition will bring an increase in 2009 operating income despite the purchase costs, with anticipated synergies contributing 25% to income in the long term.
In other news, the firm has won its legal battle with Stutgart-based firm Celesio over the shares it holds in Andreae-Noris Zahn (Anzag), according to the Pharma Adhoc news service.
The District Court of Munich rejected Celesio's claim that Sanacorp had violated an agreement to offer its Anzag shares to opposition sides before third parties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze